Fertility benefits company Progyny (NASDAQ: PGNY) will be reporting earnings tomorrow after the bell. Here’s what to look for.
Progyny beat analysts’ revenue expectations by 7.6% last quarter, reporting revenues of $298.4 million, up 10.6% year on year. It was a very strong quarter for the company, with an impressive beat of analysts’ sales volume estimates and EBITDA guidance for next quarter exceeding analysts’ expectations.
Is Progyny a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Progyny’s revenue to grow 11% year on year to $308.7 million, improving from the 7.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.45 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Progyny has missed Wall Street’s revenue estimates four times over the last two years.
Looking at Progyny’s peers in the health insurance providers segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Alignment Healthcare delivered year-on-year revenue growth of 47.5%, beating analysts’ expectations by 4.4%, and CVS Health reported revenues up 7%, topping estimates by 1.5%. Alignment Healthcare traded down 7% following the results while CVS Health was up 1.2%.
Read our full analysis of Alignment Healthcare’s results here and CVS Health’s results here.
There has been positive sentiment among investors in the health insurance providers segment, with share prices up 5.9% on average over the last month. Progyny is up 8.2% during the same time and is heading into earnings with an average analyst price target of $26.75 (compared to the current share price of $23.28).
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
